blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3316886

EP3316886 - METHODS AND COMPOUNDS FOR THE ALLEVIATION AND/OR PREVENTION OF PAIN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.03.2023
Database last updated on 28.05.2024
FormerThe patent has been granted
Status updated on  15.04.2022
FormerGrant of patent is intended
Status updated on  13.12.2021
FormerExamination is in progress
Status updated on  19.08.2019
FormerRequest for examination was made
Status updated on  06.04.2018
FormerThe international publication has been made
Status updated on  13.01.2017
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024 [2024/22]
Applicant(s)For all designated states
Svensson, Camilla
Wargentinsgatan 2
112 29 Stockholm / SE
For all designated states
Klareskog, Lars
Vanadisvägen 22B
113 46 Stockholm / SE
For all designated states
Malmström, Vivianne
Vintertullstorget 16
116 43 Stockholm / SE
For all designated states
Catrina, Anca
Brobyvägen 23 A
187 35 Täby / SE
[2018/19]
Inventor(s)01 / see applicant
...
 [2018/19]
Representative(s)Kransell & Wennborg KB
P.O. Box 27834
115 93 Stockholm / SE
[2018/19]
Application number, filing date16739596.130.06.2016
[2018/19]
WO2016SE50664
Priority number, dateUS201562188499P03.07.2015         Original published format: US 201562188499 P
US201562221119P21.09.2015         Original published format: US 201562221119 P
US201562221134P21.09.2015         Original published format: US 201562221134 P
US201562221133P21.09.2015         Original published format: US 201562221133 P
US201562221122P21.09.2015         Original published format: US 201562221122 P
US201662303452P04.03.2016         Original published format: US 201662303452 P
[2018/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017007403
Date:12.01.2017
Language:EN
[2017/02]
Type: A1 Application with search report 
No.:EP3316886
Date:09.05.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 12.01.2017 takes the place of the publication of the European patent application.
[2018/19]
Type: B1 Patent specification 
No.:EP3316886
Date:18.05.2022
Language:EN
[2022/20]
Search report(s)International search report - published on:EP12.01.2017
ClassificationIPC:A61K31/496, A61K31/341, A61K31/165, A61P29/00
[2018/19]
CPC:
A61K31/496 (EP); A61K31/165 (EP); A61K31/341 (EP);
A61P29/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/19]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN UND VERBINDUNGEN ZUR LINDERUNG UND/ODER PRÄVENTION VON SCHMERZEN[2018/19]
English:METHODS AND COMPOUNDS FOR THE ALLEVIATION AND/OR PREVENTION OF PAIN[2018/19]
French:MÉTHODES ET COMPOSÉS D'ATTÉNUATION ET/OU DE PRÉVENTION DE LA DOULEUR[2018/19]
Entry into regional phase02.02.2018National basic fee paid 
02.02.2018Designation fee(s) paid 
02.02.2018Examination fee paid 
Examination procedure25.04.2017Request for preliminary examination filed
International Preliminary Examining Authority: EP
02.02.2018Amendment by applicant (claims and/or description)
02.02.2018Examination requested  [2018/19]
02.02.2018Date on which the examining division has become responsible
22.08.2019Despatch of a communication from the examining division (Time limit: M06)
20.02.2020Reply to a communication from the examining division
21.09.2020Despatch of a communication from the examining division (Time limit: M03)
25.11.2020Reply to a communication from the examining division
14.12.2021Communication of intention to grant the patent
12.04.2022Fee for grant paid
12.04.2022Fee for publishing/printing paid
12.04.2022Receipt of the translation of the claim(s)
Divisional application(s)EP22172336.4  / EP4140486
Opposition(s)21.02.2023No opposition filed within time limit [2023/17]
Fees paidRenewal fee
15.06.2018Renewal fee patent year 03
11.06.2019Renewal fee patent year 04
12.06.2020Renewal fee patent year 05
31.05.2021Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.06.2016
CY11.05.2022
MK11.05.2022
AL18.05.2022
AT18.05.2022
CZ18.05.2022
DK18.05.2022
EE18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
IT18.05.2022
LT18.05.2022
LV18.05.2022
MC18.05.2022
NL18.05.2022
PL18.05.2022
RO18.05.2022
RS18.05.2022
SE18.05.2022
SI18.05.2022
SK18.05.2022
SM18.05.2022
BE30.06.2022
LU30.06.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
[2024/22]
Former [2024/20]HU30.06.2016
CY11.05.2022
AL18.05.2022
AT18.05.2022
CZ18.05.2022
DK18.05.2022
EE18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
IT18.05.2022
LT18.05.2022
LV18.05.2022
MC18.05.2022
NL18.05.2022
PL18.05.2022
RO18.05.2022
RS18.05.2022
SE18.05.2022
SI18.05.2022
SK18.05.2022
SM18.05.2022
BE30.06.2022
LU30.06.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
Former [2024/18]HU30.06.2016
AL18.05.2022
AT18.05.2022
CZ18.05.2022
DK18.05.2022
EE18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
IT18.05.2022
LT18.05.2022
LV18.05.2022
MC18.05.2022
NL18.05.2022
PL18.05.2022
RO18.05.2022
RS18.05.2022
SE18.05.2022
SI18.05.2022
SK18.05.2022
SM18.05.2022
BE30.06.2022
LU30.06.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
Former [2024/11]AL18.05.2022
AT18.05.2022
CZ18.05.2022
DK18.05.2022
EE18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
IT18.05.2022
LT18.05.2022
LV18.05.2022
MC18.05.2022
NL18.05.2022
PL18.05.2022
RO18.05.2022
RS18.05.2022
SE18.05.2022
SI18.05.2022
SK18.05.2022
SM18.05.2022
BE30.06.2022
LU30.06.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
Former [2023/25]AL18.05.2022
AT18.05.2022
CZ18.05.2022
DK18.05.2022
EE18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
LT18.05.2022
LV18.05.2022
MC18.05.2022
NL18.05.2022
PL18.05.2022
RO18.05.2022
RS18.05.2022
SE18.05.2022
SI18.05.2022
SK18.05.2022
SM18.05.2022
BE30.06.2022
LU30.06.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
Former [2023/21]AL18.05.2022
AT18.05.2022
CZ18.05.2022
DK18.05.2022
EE18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
LT18.05.2022
LV18.05.2022
MC18.05.2022
NL18.05.2022
PL18.05.2022
RO18.05.2022
RS18.05.2022
SE18.05.2022
SK18.05.2022
SM18.05.2022
LU30.06.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
Former [2023/17]AL18.05.2022
AT18.05.2022
CZ18.05.2022
DK18.05.2022
EE18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
LT18.05.2022
LV18.05.2022
MC18.05.2022
NL18.05.2022
PL18.05.2022
RO18.05.2022
RS18.05.2022
SE18.05.2022
SK18.05.2022
SM18.05.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
Former [2023/11]AT18.05.2022
CZ18.05.2022
DK18.05.2022
EE18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
LT18.05.2022
LV18.05.2022
MC18.05.2022
NL18.05.2022
PL18.05.2022
RO18.05.2022
RS18.05.2022
SE18.05.2022
SK18.05.2022
SM18.05.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
Former [2023/09]AT18.05.2022
CZ18.05.2022
DK18.05.2022
EE18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
LT18.05.2022
LV18.05.2022
NL18.05.2022
PL18.05.2022
RO18.05.2022
RS18.05.2022
SE18.05.2022
SK18.05.2022
SM18.05.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
Former [2023/07]AT18.05.2022
DK18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
LT18.05.2022
LV18.05.2022
NL18.05.2022
PL18.05.2022
RS18.05.2022
SE18.05.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
Former [2022/51]AT18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
LT18.05.2022
LV18.05.2022
NL18.05.2022
PL18.05.2022
RS18.05.2022
SE18.05.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
IS18.09.2022
PT19.09.2022
Former [2022/50]AT18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
LT18.05.2022
LV18.05.2022
NL18.05.2022
PL18.05.2022
RS18.05.2022
SE18.05.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
PT19.09.2022
Former [2022/49]AT18.05.2022
ES18.05.2022
FI18.05.2022
HR18.05.2022
LT18.05.2022
LV18.05.2022
NL18.05.2022
SE18.05.2022
BG18.08.2022
NO18.08.2022
GR19.08.2022
PT19.09.2022
Former [2022/48]AT18.05.2022
ES18.05.2022
FI18.05.2022
LT18.05.2022
NL18.05.2022
SE18.05.2022
NO18.08.2022
PT19.09.2022
Former [2022/47]AT18.05.2022
ES18.05.2022
FI18.05.2022
LT18.05.2022
SE18.05.2022
NO18.08.2022
PT19.09.2022
Cited inInternational search[X]  - Ahn ET AL, "GENERALPOSTERS GP67 GP67.CHANGESINEXPRESSIONOFMRNAFORINTERLEUKIN-8ANDEFFECTSOF INHIBITIONOFMICROGLIAINTHESPINALDORSALHORNINARATMODELOF LUMBARDISCHERNIATION", (20101001), URL: http://pdfs.journals.lww.com/spinejournalabstracts/2010/10001/CHANGES_IN_EXPRESSION_OF_MRNA_FOR_INTERLEUKIN_8.209.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1475158659344;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFq, (20160929), XP055306728 [X] 1-5,16,19-21 * abstract *
 [XI]  - T M CUNHA ET AL, "Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice", BRITISH JOURNAL OF PHARMACOLOGY, (20080501), vol. 154, no. 2, doi:10.1038/bjp.2008.94, ISSN 0007-1188, pages 460 - 470, XP055306654 [X] 1-4,16,19,20 * results, discussion * [I] 6,15

DOI:   http://dx.doi.org/10.1038/bjp.2008.94
 [X]  - LAZAROS I. SAKKAS ET AL, "Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment", AUTOIMMUNITY REVIEWS, NL, (20141101), vol. 13, no. 11, doi:10.1016/j.autrev.2014.08.012, ISSN 1568-9972, pages 1114 - 1120, XP055306589 [X] 23 * paragraph [0003] - paragraph [0004] *

DOI:   http://dx.doi.org/10.1016/j.autrev.2014.08.012
 [X]  - ELENA OSSIPOVA ET AL, "Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, (20140812), vol. 16, no. 4, doi:10.1186/AR4683, ISSN 1478-6354, page R167, XP021196297 [X] 23 * introduction *

DOI:   http://dx.doi.org/10.1186/ar4683
 [IP]  - AKILAN KRISHNAMURTHY ET AL, "Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss", ANNALS OF THE RHEUMATIC DISEASES, GB, (20151126), vol. 75, no. 4, doi:10.1136/annrheumdis-2015-208093, ISSN 0003-4967, pages 721 - 729, XP055306585 [IP] 1-26 * results, discussion *

DOI:   http://dx.doi.org/10.1136/annrheumdis-2015-208093
 [XP]  - GUSTAF WIGERBLAD ET AL, "Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism", ANNALS OF THE RHEUMATIC DISEASES, GB, (20151127), vol. 75, no. 4, doi:10.1136/annrheumdis-2015-208094, ISSN 0003-4967, pages 730 - 738, XP055306572 [XP] 1-26 * results, discussion *

DOI:   http://dx.doi.org/10.1136/annrheumdis-2015-208094
 [XP]  - MIKAEL BRINK ET AL, "Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis", ARTHRITIS RESEARCH & THERAPY, (20160209), vol. 9, no. 7, doi:10.1186/s13075-016-0940-2, page e101717, XP055306720 [XP] 23-26 * discussion *

DOI:   http://dx.doi.org/10.1186/s13075-016-0940-2
 [A]  - RUSSO R C ET AL, "The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases", EXPERT REVIEW OF CLINICAL IMMUNOLOGY, FUTURE DRUGS LTD., LONDON, GB, (20140501), vol. 10, no. 5, ISSN 1744-666X, pages 593 - 619, XP009187563 [A] 1-26

DOI:   http://dx.doi.org/10.1586/1744666X.2014.894886
Examination   - KRISHNAMURTHY, A. ET AL., "Anti-citrullinated proteins antibodies promotes osteoclastogenesis and bone destruction in rheumatoid arthritise", ANNALS OF THE RHEUMATIC DISEASES, GB, (20150213), vol. 74, no. Suppl 1, doi:10.1136/annrheumdis-2015-207259.100, ISSN 0003-4967, pages A43.2 - A44, XP055308033

DOI:   http://dx.doi.org/10.1136/annrheumdis-2015-207259.100
    - Ulrike Harre ET AL, "Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin", The Journal of Clinical Investigation, GB, (20120501), vol. 122, no. 5, doi:10.1172/JCI60975, ISSN 0021-9738, pages 1791 - 1802, XP055286894

DOI:   http://dx.doi.org/10.1172/JCI60975
by applicantWO2004058797
 EP1590364
 EP1628665
 US2013004416
 US8859538
    - ENDO ET AL., CLINICAL AND EXPERIMENTAL IMMUNOLOGY, (19940401), vol. 96, no. 1
    - S. RIEGSECKER; S. AHMED, FASEB, (20130401), vol. 27, page 643.18
    - TANAKA ET AL., MODERN RHEUMATOLOGY, (20120201), vol. 22, no. 1
    - ZHANG, Z.-J.; CAO, D.-L.; ZHANG, X.; JI, R.-R.; GAO, Y.-J, "Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons", PAIN, (2013), vol. 154, no. 10, doi:doi:10.1016/j.pain.2013.07.002, pages 2185 - 2197, XP028717377

DOI:   http://dx.doi.org/10.1016/j.pain.2013.07.002
    - QIN, X.; WAN, Y.; WANG, X, "CCL2 and CXCL1 trigger calcitonin gene-related peptide release by exciting primary nociceptive neurons", JOURNAL OF NEUROSCIENCE RESEARCH, (2005), vol. 82, no. 1, pages 51 - 62
    - GUERRERO, A. T. G.; CUNHA, T. M.; VERRI, W. A.; GAZZINELLI, R. T.; TEIXEIRA, M. M.; CUNHA, F. Q.; FERREIRA, S. H., "Toll-like receptor 2/MyD88 signaling mediates zymosan-induced joint hypernociception in mice: participation of TNF-a, IL-1¡3 and CXCL1/KC", EUROPEAN JOURNAL OF PHARMACOLOGY, (2012), vol. 674, no. 1, doi:doi:10.1016/j.ejphar.2011.10.023, pages 51 - 57, XP028126047

DOI:   http://dx.doi.org/10.1016/j.ejphar.2011.10.023
    - KIM, S.-J.; PARK, S.-M.; CHO, Y.-W.; JUNG, Y.-J.; LEE, D.-G.; JANG, S.-H. ET AL., "Changes in expression of mRNA for interleukin-8 and effects of interleukin-8 receptor inhibitor in the spinal dorsal horn in a rat model of lumbar disc herniation", SPINE, (2011), vol. 36, no. 25, doi:doi:10.1097/BRS.0b013e31821945a3, pages 2139 - 2146, XP055377245

DOI:   http://dx.doi.org/10.1097/BRS.0b013e31821945a3
    - CUI, G.-B.; AN, J.-Z.; ZHANG, N.; ZHAO, M.-G.; LIU, S.-B.; YI, J., "Elevated interleukin-8 enhances prefrontal synaptic transmission in mice with persistent inflammatory pain", MOLECULAR PAIN, (2012), vol. 8, no. 1, doi:doi:10.1186/1744-8069-8-11, page 11, XP021118958

DOI:   http://dx.doi.org/10.1186/1744-8069-8-11
    - GREEN; ROGERS, "Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption", DRUG DEVELOPMENT RESEARCH, (200204), vol. 55, no. 4, doi:doi:10.1002/ddr.10071, pages 210 - 224, XP009024825

DOI:   http://dx.doi.org/10.1002/ddr.10071
    - AMARA, K. ET AL., "Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition", J EXP MED, (2013), vol. 210, pages 445 - 455
    - ARNETT, F. C. ET AL., "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", ARTHRITIS RHEUM, (1988), vol. 31, pages 315 - 324
    - BAS, D. B ET AL., "Collagen antibody-induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency", ARTHRITIS RHEUM, (2012), vol. 64, pages 3886 - 3896
    - BOS, W. H. ET AL., "Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis", THE JOURNAL OF RHEUMATOLOGY, (2008), vol. 35, pages 1972 - 1977
    - BOS, W. H. ET AL., "Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study", ANN RHEUM DIS, (2010), vol. 69, pages 490 - 494
    - CAO, D.-L.; ZHANG, Z.-J.; XIE, R.-G.; JIANG, B.-C.; JI, R.-R.; GAO, Y.-J., "Chemokine CXCL1 enhances inflammatory pain and increases NMDA receptor activity and COX-2 expression in spinal cord neurons via activation of CXCR2", EXPERIMENTAL NEUROLOGY, (201411), vol. 261, pages 328 - 36
    - CATRINA AI; JOSHUA V; KLARESKOG L; MALMSTROM V., "Mechanisms involved in triggering rheumatoid arthritis", IMMUNOL REV., (201601), vol. 269, no. 1, pages 162 - 74
    - CHAPLAN, S. R.; BACH, F. W.; POGREL, J. W.; CHUNG, J. M; YAKSH, T. L., "Quantitative assessment of tactile allodynia in the rat paw", JOURNAL OF NEUROSCIENCE METHODS, (1994), vol. 53, doi:doi:10.1016/0165-0270(94)90144-9, pages 55 - 63, XP024352718

DOI:   http://dx.doi.org/10.1016/0165-0270(94)90144-9
    - COBOS, E. J ET AL., "Inflammation-induced decrease in voluntary wheel running in mice: a nonreflexive test for evaluating inflammatory pain and analgesia", PAIN, (2012), vol. 153, doi:doi:10.1016/j.pain.2012.01.016, pages 876 - 884, XP028471172

DOI:   http://dx.doi.org/10.1016/j.pain.2012.01.016
    - CUI, G.-B; AN, J.-Z.; ZHANG, N.; ZHAO, M.-G.; LIU, S.-B.; YI, J., "Elevated interleukin-8 enhances prefrontal synaptic transmission in mice with persistent inflammatory pain", MOLECULAR PAIN, (20120212), vol. 8, no. 1, doi:doi:10.1186/1744-8069-8-11, page 11, XP021118958

DOI:   http://dx.doi.org/10.1186/1744-8069-8-11
    - CUNHA, T. M. ET AL., "A cascade of cytokines mediates mechanical inflammatory hypernociception in mice.", PROC NATL ACAD SCI USA, (2005), vol. 102, pages 1755 - 1760
    - DIRIG, D. M.; SALAMI, A.; RATHBUN, M. L.; OZAKI, G. T.; YAKSH, T. L., "Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli", JOURNAL OF NEUROSCIENCE METHODS, (1997), vol. 76, doi:doi:10.1016/S0165-0270(97)00097-6, pages 183 - 191, XP004902359

DOI:   http://dx.doi.org/10.1016/S0165-0270(97)00097-6
    - NANDAKUMAR, K. S.; SVENSSON, L; HOLMDAHL, R., "Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes", AM. J. PATHOL., (2003), vol. 163, pages 1827 - 1837, XP002582846
    - ENDO ET AL., "Experimental arthritis induced by continuous infusion of IL-8 into rabbit knee joints", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, (19940401), vol. 96, no. 1
    - GREEN, JONATHAN R; ROGERS, MICHAEL J., "Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption", DRUG DEVELOPMENT RESEARCH, (200204), vol. 55, no. 4, doi:doi:10.1002/ddr.10071, pages 210 - 224, XP009024825

DOI:   http://dx.doi.org/10.1002/ddr.10071
    - GUERRERO, A. T. G ET AL., "Toll-like receptor 2/MyD88 signaling mediates zymosan-induced joint hypernociception in mice: participation of TNF-a, IL-1¡3 and CXCL1/KC", EUR J PHARMACOL, (2012), vol. 674, doi:doi:10.1016/j.ejphar.2011.10.023, pages 51 - 57, XP028126047

DOI:   http://dx.doi.org/10.1016/j.ejphar.2011.10.023
    - GULER-YUKSEL, M ET AL., "Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis", ANN RHEUM DIS, (2009), vol. 68, doi:doi:10.1136/ard.2007.086348, pages 330 - 336, XP002551324

DOI:   http://dx.doi.org/10.1136/ard.2007.086348
    - HARRE, U. ET AL., "Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin", J CLIN INVEST, (2012), vol. 122, doi:doi:10.1172/JCI60975, pages 1791 - 1802, XP055286894

DOI:   http://dx.doi.org/10.1172/JCI60975
    - HOARAU, J.-J. ET AL., "Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response", J IMMUNOL, (2010), vol. 184, pages 5914 - 5927
    - IBARRA, J. M.; JIMENEZ, F.; MARTINEZ, H. G.; CLARK, K.; AHUJA, S. S, "MMP-Activated Fluorescence Imaging Detects Early Joint Inflammation in Collagen-Antibody-Induced Arthritis in CC-Chemokine Receptor-2-Null Mice, In-Vivo", INT J INFLAM, (2011), page 691587
    - KLEIN, C. J; LENNON, V. A.; ASTON, P. A.; MCKEON, A.; PITTOCK, S. J., "Chronic pain as a manifestation of potassium channel-complex autoimmunity", NEUROLOGY, (2012), vol. 79, doi:doi:10.1212/WNL.0b013e3182698cab, pages 1136 - 1144, XP002720265

DOI:   http://dx.doi.org/10.1212/WNL.0b013e3182698cab
    - KOPESKY, P. ET AL., "Autocrine signaling is a key regulatory element during osteoclastogenesis", BIOL OPEN, (2014), vol. 3, pages 767 - 776
    - KRISHNAMURTHY, A ET AL., "Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone destruction", ANN RHEUM DIS., (201604), vol. 75, doi:doi:10.1136/annrheumdis-2015-208093, pages 721 - 9, XP055306585

DOI:   http://dx.doi.org/10.1136/annrheumdis-2015-208093
    - LEE, Y. C ET AL., "Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study", ARTHRITIS RES THER, (2011), vol. 13, doi:doi:10.1186/ar3353, page R83, XP021104462

DOI:   http://dx.doi.org/10.1186/ar3353
    - MAKRYGIANNAKIS, D. ET AL., "Citrullination is an inflammation-dependent process", ANN RHEUM DIS, (2006), vol. 65, doi:doi:10.1136/ard.2005.049403, pages 1219 - 1222, XP009182852

DOI:   http://dx.doi.org/10.1136/ard.2005.049403
    - MECHIN, M.C. ET AL., "The peptidylarginine deiminases expressed in human epidermis differ in their substrate specificities and subcellular locations", CELLULAR AND MOLECULAR LIFE SCIENCES : CMLS, (2005), vol. 62, doi:doi:10.1007/s00018-005-5196-y, pages 1984 - 1995, XP019200821

DOI:   http://dx.doi.org/10.1007/s00018-005-5196-y
    - OSSIPOVA, E ET AL., "Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint", ARTHRITIS RES THER, (2014), vol. 16, doi:doi:10.1186/ar4683, page R167, XP021196297

DOI:   http://dx.doi.org/10.1186/ar4683
    - PHUKLIA, W. ET AL., "Osteoclastogenesis induced by CHIKV-infected fibroblast-like synoviocytes: a possible interplay between synoviocytes and monocytes/macrophages in CHIKV-induced arthralgia/arthritis", VIRUS RES., (2013), vol. 177, doi:doi:10.1016/j.virusres.2013.08.011, pages 179 - 188, XP028735778

DOI:   http://dx.doi.org/10.1016/j.virusres.2013.08.011
    - QIN, X.; WAN, Y; WANG, X, "CCL2 and CXCL1 trigger calcitonin gene-related peptide release by exciting primary nociceptive neurons", J. NEUROSCI. RES., (2005), vol. 82, pages 51 - 62
    - RANTAPAA-DAHLQVIST S; E JONG BA; BERGLIN E; HALLMANS G; WADELL G; STENLUND H; SUNDIN U; VAN VENROOIJ WJ, "Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis", ARTHRITIS RHEUM, (200310), vol. 48, no. 10, doi:doi:10.1002/art.11223, pages 2741 - 9, XP002333657

DOI:   http://dx.doi.org/10.1002/art.11223
    - REDDY V; MANI RS; DESAI A; RAVI V, "Correlation of plasma viral loads and presence of Chikungunya IgM antibodies with cytokine/chemokine levels during acute Chikungunya virus infection", J MED VIROL., (201408), vol. 86, no. 8, pages 1393 - 401
    - RUSSO, R. C.; GARCIA, C. C.; TEIXEIRA, M. M.; AMARAL, F. A, "The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases", EXPERT REV CLIN IMMUNOL, (2014), vol. 10, doi:doi:10.1586/1744666X.2014.894886, pages 593 - 619, XP009187563

DOI:   http://dx.doi.org/10.1586/1744666X.2014.894886
    - RONNELID, J. ET AL., "Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression", ANN RHEUM DIS, (2005), vol. 64, pages 1744 - 1749
    - SCHELLEKENS, G. A.; DE JONG, B. A.; VAN DEN HOOGEN, F. H.; VAN DE PUTTE, L. B.; VAN VENROOIJ, W. J, "Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies", J CLIN INVEST, (1998), vol. 101, doi:doi:10.1172/JCI1316, pages 273 - 281, XP000749589

DOI:   http://dx.doi.org/10.1172/JCI1316
    - TAKAHARA, H.; OKAMOTO, H.; SUGAWARA, K., "Calcium-Dependent Properties of Peptidylarginine Deiminase from Rabbit Skeletal-Muscle", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, (1986), vol. 50, pages 2899 - 2904
    - VERRI, W. A. ET AL., "Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development?", PHARMACOL. THER., (2006), vol. 112, doi:doi:10.1016/j.pharmthera.2006.04.001, pages 116 - 138, XP025038567

DOI:   http://dx.doi.org/10.1016/j.pharmthera.2006.04.001
    - VOSSENAAR, E.R.; ZENDMAN, A.J.W.; VAN VENROOIJ, W.J; PRUIJN, G.J.M, "PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease", BIOESSAYS : NEWS AND REVIEWS IN MOLECULAR, CELLULAR AND DEVELOPMENTAL BIOLOGY, (2003), vol. 25, doi:doi:10.1002/bies.10357, pages 1106 - 1118, XP008057229

DOI:   http://dx.doi.org/10.1002/bies.10357
    - WANG, J.-G. ET AL., "The chemokine CXCL1/growth related oncogene increases sodium currents and neuronal excitability in small diameter sensory neurons", MOLECULAR PAIN, (2008), vol. 4, doi:doi:10.1186/1744-8069-4-38, page 38, XP021045085

DOI:   http://dx.doi.org/10.1186/1744-8069-4-38
    - WHITE JR; LEE JM; YOUNG PR; HERTZBERG RP; JUREWICZ AJ; CHAIKIN MA; WIDDOWSON K; FOLEY JJ; MARTIN LD; GRISWOLD DE, "Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration", J BIOL CHEM., (19980424), vol. 273, no. 17, pages 10095 - 8
    - ZHANG, Z.-J.; CAO, D.-L.; ZHANG, X.; JI, R.-R; GAO, Y.-J., "Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons", PAIN, (2013), vol. 154, doi:doi:10.1016/j.pain.2013.07.002, pages 2185 - 2197, XP028717377

DOI:   http://dx.doi.org/10.1016/j.pain.2013.07.002
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.